October 01, 2014 2:56 AM ET

Life Sciences Tools and Services

Company Overview of GnuBIO, Inc.

Company Overview

GnuBIO, Inc. develops DNA sequencing systems for clinical and research applications. The company offers beta system instruments and single consumable cartridges for the interrogation of single genes, gene panels, or whole genomes. It provides systems for DNA sequencing, including target selection/enrichment, DNA amplification, DNA sequencing, and analysis. The company was founded in 2009 and is based in Cambridge, Massachusetts. As of April 10, 2014, GnuBIO, Inc. operates as a subsidiary of Bio-Rad Laboratories, Inc.

64 Sidney Street

Suite 380

Cambridge, MA 02139

United States

Founded in 2009

Phone:

617-446-6744

Fax:

617-446-6748

Key Executives for GnuBIO, Inc.

Co-Founder
Co-Founder and Advisor
Chief Financial Officer
Executive Vice President of Product Development
Vice President of Informatics
Compensation as of Fiscal Year 2014.

GnuBIO, Inc. Key Developments

GnuBIO, Inc. Presents at Cowen and Company, LLC's 33rd Annual Health Care Conference, Mar-05-2013 08:30 AM

GnuBIO, Inc. Presents at Cowen and Company, LLC's 33rd Annual Health Care Conference, Mar-05-2013 08:30 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: John J. Boyce, Co-Founder, Chief Executive Officer and President.

GnuBIO, Inc. to Unveil the Prototype Fully Integrated DNA Sequencer at the Association of Molecular Pathology Conference

GnuBIO, Inc. announced that it will unveil the prototype of the fully integrated DNA sequencer (the K-cup coffee cartridge model of DNA sequencing) at the Association of Molecular Pathology (AMP) conference, booth #330, from October 25(th) -- October 27(th) . The prototype system that the company will unveil at AMP has the exact dimensions and configurations of both the beta and commercial system that will be launched shortly. The prototype is built around optics, electronics and process controls that are installed within the systems running in house. The GnuBIO system has a completely integrated workflow, inclusive of genomic selection, amplification, sequencing and real time informatics (assembly and variant calling), allowing researchers and clinicians to simply inject genomic DNA, and walk away -- with data provided on the targeted regions within a few hours.

Gnubio, Inc. Promotes Susie Truong Harborth as Chief Financial Officer

GnuBIO, Inc. announced that Susie Truong Harborth has been promoted to Chief Financial Officer. Ms. Harborth has been with GnuBIO since the company's inception and will continue to lead finance, human resources and operations of the company while taking on new responsibilities for company strategy.

Similar Private Companies By Industry

Company Name Region
Sartorius Stedim Freeze Thaw Inc. United States
Symphony Clinical Research United States
InCube Labs, LLC United States
BioAtla, LLC United States
Summit Drug Development Services LLC United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
April 10, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GnuBIO, Inc., please visit www.gnubio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.